Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EBITDA (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of EBITDA data on record, last reported at $17.4 million in Q4 2025.

  • For Q4 2025, EBITDA rose 253.72% year-over-year to $17.4 million; the TTM value through Dec 2025 reached -$16.2 million, up 88.45%, while the annual FY2025 figure was -$16.2 million, 88.45% up from the prior year.
  • EBITDA reached $17.4 million in Q4 2025 per ARQT's latest filing, up from $7.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $17.4 million in Q4 2025 and bottomed at -$108.1 million in Q3 2022.
  • Average EBITDA over 5 years is -$46.8 million, with a median of -$48.6 million recorded in 2023.
  • Peak YoY movement for EBITDA: plummeted 110.14% in 2021, then soared 253.72% in 2025.
  • A 5-year view of EBITDA shows it stood at -$71.6 million in 2021, then grew by 0.08% to -$71.5 million in 2022, then rose by 7.57% to -$66.1 million in 2023, then skyrocketed by 82.86% to -$11.3 million in 2024, then skyrocketed by 253.72% to $17.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $17.4 million in Q4 2025, $7.4 million in Q3 2025, and -$15.8 million in Q2 2025.